Proactive Investors - Run By Investors For Investors

ImmuPharma extends exclusivity period for its collaboration talks with Incanthera

ImmuPharma and Incanthera are making good progress in finalising the definitive licence agreement
Cogs of collaboration
The wheels are turning but it has not been possible to complete negotiations by the deadline

The exclusivity agreement between ImmuPharma PLC (LON:IMM) and Incanthera Limited, due to expire at midnight today, has been extended to the end of March.

ImmuPharma announced on 7 September a clinical development collaboration for its Nucant cancer programme with specialist oncology development company, Incanthera, but it has yet to finalise the definitive licence agreement'.

REA: ImmuPharma says managed access programme for Lupozor progressing as planned

It is now envisaged that the agreement will be finalised in the first quarter of 2019 and as such, a further update on this collaboration will be announced in due course.

"We are working diligently with Incanthera's management team to finalise the last remaining parts to the 'Definitive Licence Agreement' and look forward to updating the market and shareholders in Q1 2019,” said Dimitri Dimitriou, the chief executive officer of ImmuPharma.

View full IMM profile View Profile

ImmuPharma PLC Timeline

Related Articles

pills
January 15 2019
Under former chief executive Peter George and his successor Shaun Chilton, Clinigen has been transformed via a series of well-judged, quickly integrated and cash generative acquisitions
picture of a knee
May 20 2019
We take a closer look at Collagen Solutions, which received third-party validation of its business model in the form of outside investment from a blue-chip US agriculture company
young girl with allergy
April 29 2019
The sell-off that followed the recent disappointment of Allergy’s PQ Birch jab means now might be a good time to invest, according to City broker finnCap

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use